Oscar Health Announces Financial Results for Third Quarter 2026 and Raises Full
Oscar Health Announces Financial Results for Third Quarter 2026 and Raises Full Year 2026 Outlook
Oscar Health, Inc. (“Oscar Health” or the “Company”) (NYSE: OSCR) announced today its financial results for the third quarter ended September 30, 2026, and updates to its full year 2026 outlook.
“Oscar Health is on track to deliver the strongest year of financial performance in our history, and we are raising our earnings from operations outlook for a third time,” said Mark Bertolini, CEO of Oscar Health. “The ACA is the foundation of a rapidly-developing individual market in America, and Oscar Health is built to lead it. Our disciplined pricing, consumer-led products, and technology-powered approach are driving stronger economics and position us to grow market share and expand margin in 2027.”
Three Months Nine Months Ended Ended September 30, September 30, (in thousands, 2026 2025 2026 2025 except percentages) Total revenue $5,139,298 $2,985,984 $14,666,712 $8,896,192 Medical loss 84.0% 88.5% 78.1% 84.8% ratio (“MLR”) Selling, general, and administrati… 14.0% 17.5% 14.4% 17.3% (“SG&A”) expense ratio Earnings (loss) from $178,018 $(129,250) $1,270,738 $(62,610) operations Net income (loss) attributable $167,281 $(137,450) $1,208,085 $(90,540) to Oscar Health, Inc. Adjusted $206,852 $(101,453) $1,349,273 $27,971 EBITDA(1) (1) Adjusted EBITDA is a non-GAAP measure. See “Key Operating and Non-GAAP Financial Metrics - Adjusted EBITDA” in this release for a reconciliati… to net income, the most directly comparable GAAP measure, and for information regarding Oscar Health’s use of Adjusted EBITDA.
As of September 30, Effectuated Membership by Offering 2026 2025 Individual and Small Group(1) 2,691,885 2,111,736 Cigna+Oscar(2) — 5,168 Total Members(3) 2,691,885 2,116,904 (1) Membership includes members enrolled through a Custom Health Option and Individual Care Expense Arrangement (“CHOICE”). 2025 membership includes small group members. The Company no longer offers small group plans effective December 15, 2024. (2) Represents total membership for our former co-branded partnership with Cigna. We did not renew the Cigna+Oscar Small Group arrangement after its initial term ended on December 31, 2024. (3) Represents effectuated members. Effectuated members are those who are actively enrolled in one of our plans and whose required premium payments have either been made or are within the payment grace period. A member covered under more than one of our health plans counts as a single member for the purposes of this metric.
2026 Financial Guidance Summary Prior Full Updated Full Year 2026 Year 2026 Outlook Outlook (in thousands, Low High Low High except percentage… Total $18.7 $19.0 $19.0 billion $19.3 revenue(1) billion billion billion Medical loss 81.0% 82.0% 80.5% 81.5% ratio(2) SG&A expense 15.6% 16.1% 15.1% 15.6% ratio(3) Earnings from $600 million $800 million $850 million $950 million operations… (1) Total revenue includes premium revenue (net of risk adjustment transfers), investment income, and other revenue. We believe total revenue is an important metric to assess the growth of our business, as well as the earnings potential of our investment portfolio. (2) Medical loss ratio (MLR) is a metric used to calculate medical expenses as a percentage of net premiums before ceded quota share reinsuranc… We believe MLR is an important metric to demonstrate the ratio of our costs to pay for the healthcare of our members to the net premiums before ceded quota share reinsuranc… (3) Selling, general, and administra… (SG&A) expense ratio is calculated as selling, general and administra… expenses as a percentage of total revenue (net of risk adjustment transfers). We believe the SG&A expense ratio is useful to evaluate our ability to manage our overall selling, general, and administra… cost base. (4) Earnings from operations is the Company's total revenue less total operating expenses. We believe earnings from operations is an important primary metric for assessing operating performanc…
• Total revenue was approximately $5.1 billion for the third quarter of 2026 compared to $3.0 billion for the third quarter of 2025. The increase was driven by rate increases and higher membership. Revenue for the third quarter of 2026 included a $250 million benefit from updated risk adjustment estimates, driven by favorable development in the Company’s risk scores relative to the market and modestly favorable market morbidity relative to expectations.
• The medical loss ratio was 84.0% for the third quarter of 2026 compared to 88.5% for the third quarter of 2025. The decrease was primarily driven by our disciplined pricing strategy. The Company had $42 million of favorable prior period development in the third quarter of 2026 compared to $84 million of favorable prior period development in the third quarter of 2025.
• The SG&A expense ratio was 14.0% for the third quarter of 2026 compared to 17.5% for the third quarter of 2025. The decrease was primarily due to lower risk adjustment as a percentage of premium, greater fixed cost leverage, and disciplined expense management.
• Earnings from operations were $178.0 million for the third quarter of 2026 compared to a loss from operations of $129.3 million for the third quarter of 2025. The significant increase reflects strong operating performance driven primarily by improved underwriting performance.
• Net income attributable to Oscar Health, Inc. was $167.3 million, or $0.49 of diluted earnings per share, for the third quarter of 2026 compared to net loss attributable to Oscar Health, Inc. of $137.5 million, or $(0.53) of diluted loss per share, for the third quarter of 2025.
• Adjusted EBITDA was $206.9 million for the third quarter of 2026 compared to an adjusted EBITDA loss of $101.5 million for the third quarter of 2025. 2
Oscar Health will host a conference call to discuss its financial results today, November 5, 2026, at 8:00 a.m. (ET). A live audio webcast will be available online via the Investor Relations page of Oscar Health’s website at ir.oscarhealth.com. A replay of the webcast will be available for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
This release presents adjusted EBITDA, a non-GAAP financial metric, which is provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America (“GAAP”). A reconciliation of historical non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release. For more information regarding adjusted EBITDA, please see “Key Operating and Non-GAAP Financial Metrics” below.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained herein are forward-looking statements. These statements include, but are not limited to, statements about our financial outlook and estimates, including Total revenue, Medical loss ratio, SG&A expense ratio, Earnings (loss) from operations, and other financial performance metrics, and the related underlying assumptions, our business and financial prospects, including management’s plans and objectives for future operations, expectations and business strategy, such as our margins, market share and profitability, and industry and market dynamics and expected trends. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “forecasts,” “predicts,” “potential,” or “continues” or the negative of these terms or other similar expressions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, and uncertainties that are difficult to predict and generally beyond our control.
Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, there are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our ability to execute our strategy and manage our growth effectively (including our ability to successfully integrate strategic acquisitions); our ability to retain and expand our member base; our ability to accurately estimate our incurred medical expenses or overall market morbidity, or effectively manage our medical costs or related administrative costs; unanticipated results of, or changes to, risk adjustment programs or our estimates thereof; evolving federal or state laws or regulations (including any changes in the interpretation or enforcement of existing laws and regulations), including changes with respect to the Patient Protection and Affordable Care Act (“ACA”) and any regulations enacted thereunder, the expiration of the enhanced Advanced Premium Tax Credits, the implementation of new program integrity rules, such as ID proofing rules, and rules pursuant to the Notice of Benefit and Payment Parameters for policy year 2027, the potential funding of a cost-sharing reduction program, or other government actions, such as the imposition of tariffs; our ability to achieve or maintain profitability in the future; our ability to arrange for the delivery of quality care and maintain good relations with brokers and the physicians, hospitals, and other providers within and outside our provider networks; our ability to comply with ongoing, complex and evolving regulatory requirements, including capital reserve and surplus requirements and applicable performance standards; changes or developments in the regulation of health insurance markets in the United States; our, or any of our vendors’, ability to comply with laws, regulations, and standards related to the handling of information about individuals or applicable consumer protection laws, including as a result of our participation in government-sponsored programs; the ability of our health insurance and Health Maintenance Organization subsidiaries to make payments of dividends or distributions to us, including to fund our business strategy; our ability to utilize quota share reinsurance to meet our capital and surplus requirements and protect against downside risk on medical claims; adverse market conditions resulting in our investment portfolio suffering losses or reducing our ability to meet our financing needs; unfavorable or otherwise costly outcomes of lawsuits, audits, investigations, and other third party claims that may arise from the extensive laws and regulations to which we are subject, such as fraud, waste and abuse laws; incurrence of data security breaches of our or our partners’ information and technology systems; heightened competition in the markets in which we participate; our ability to attract and retain qualified personnel; uncertainties associated with our utilization of certain artificial intelligence and machine learning models; our ability to detect and prevent material weaknesses or significant control deficiencies in our internal controls over financial reporting or other failure to maintain an effective system of internal controls; adverse publicity or other adverse consequences related to our dual class structure or “controlled company” status; and the other factors set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”), and our other filings with the SEC. 3
You are cautioned not to place undue reliance on any forward-looking statements made in this press release. Any forward-looking statement speaks only as of the date as of which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time to time, and it is not possible for us to predict which will arise.
Oscar Health, Inc. (NYSE: OSCR) is a leading consumer healthcare company that gives people power over their healthcare. Oscar Health serves millions of consumers, employers, brokers, and partners through Oscar Insurance, Lucie Health Marketplace, and Trove Group. Together these businesses deliver exceptional lifestyle products and technology platforms that make healthcare easy to choose, use, and experience. Learn more at OscarHealth.com.
(in thousands, except per September 30, December 31, share amounts) 2026 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current Assets: Cash and cash $ 4,466,858 $ 2,774,151 equivalents Short-term 3,021,732 1,216,461 investments Accounts receivable (net of allowance for credit 303,302 362,682 losses of $19,131 and $7,226) Reinsurance 270,643 99,750 recoverable Receivables 193,793 136,029 from CMS Other current 59,831 24,331 assets Total current 8,316,159 4,613,404 assets Long-term 1,441,909 1,470,987 investments Property, equipment, and 109,312 88,350 capitalized software, net Restricted 27,484 32,951 deposits Other assets 114,116 119,719 Total assets $ 10,008,980 $ 6,325,411 Liabilities and Stockholders' Equity Current Liabilities: Payables to CMS $ 4,626,054 $ 2,730,095 Benefits 1,924,075 1,455,385 payable Accounts payable and 589,220 507,325 other liabilities Unearned 160,392 166,203 premiums Reinsurance 1,711 3,579 payable Total current 7,301,452 4,862,587 liabilities Long-term debt 432,410 430,095 Other 49,324 51,994 liabilities Total 7,783,186 5,344,676 liabilities Commitments and contingencies Stockholders' Equity Class A common stock ($0.00001 par value; 825,000 thousand shares authorized, 275,454 thousand and 261,851 3 3 thousand shares outstanding as of September 30, 2026 and December 31, 2025, respectively) Class B common stock ($0.00001 par value; 82,500 thousand shares authorized, 35,176 thousand and 35,838 — — thousand shares outstanding as of September 30, 2026 and December 31, 2025, respectively) Treasury stock (315 thousand shares as of September -2,923 -2,923 30, 2026 and December 31, 2025) Additional 4,353,570 4,256,972 paid-in capital Accumulated -2,086,349 -3,294,434 deficit Accumulated other comprehensive -41,664 18,030 income (loss) Total Oscar Health, Inc. 2,222,637 977,648 stockholders' equity Noncontrolling 3,157 3,087 interests Total stockholders' 2,225,794 980,735 equity Total liabilities and $ 10,008,980 $ 6,325,411 stockholders' equity
(in thousands) Cash Flows from Nine Months Ended Operating September 30, Activities: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income (loss) $ 1,208,155 $ -90,469 Adjustments to reconcile net income (loss) to net cash provided by operating activities: Change in provision 11,905 -24,020 for credit losses Stock-based 58,914 69,569 compensation expense Depreciation and 19,592 21,012 amortization expense Amortization of debt 3,339 774 issuance costs Net accretion of -22,975 -23,066 investments Deferred taxes -4,313 -175 Net realized gain on sale of financial -1,907 -1,302 instruments Changes in assets and liabilities: (Increase) / decrease in: Reinsurance -170,893 132,146 recoverable Accounts receivable 47,474 -54,402 Receivables from CMS -57,764 -78,240 Other assets -21,608 -29,759 Increase / (decrease) in: Payables to CMS 1,895,959 266,501 Benefits payable 468,691 207,665 Accounts payable and 83,847 58,061 other liabilities Unearned premiums -5,811 2,727 Reinsurance payable -1,868 -34,071 Net cash provided by operating 3,510,737 422,951 activities Cash Flows from Investing Activities: Sale of investments 1,149,495 134,231 Maturity and paydowns of 1,614,749 478,173 investments Change in restricted 211 3,225 deposits Purchase of -4,578,517 -780,673 investments Purchase of property, equipment, -31,864 -27,310 and capitalized software Net cash used in -1,845,926 -192,354 investing activities Cash Flows from Financing Activities: Proceeds from — 410,000 long-term debt Proceeds from exercise of stock options 41,828 42,192 and stock purchase agreement Tax payments related to net settlement -11,920 -4,035 of share-based awards Purchase of capped calls related to — -34,440 convertible notes Payments of debt -5,990 -22,677 issuance costs Earn-out liability -3,370 — payout Net cash provided by financing 20,548 391,040 activities Increase in cash, cash equivalents and 1,685,359 621,637 restricted cash equivalents Cash, cash equivalents, restricted cash 2,804,123 1,551,118 and cash equivalents—beginni… of period Cash, cash equivalents,restric… cash 4,489,482 2,172,755 and cash equivalents—end of period Cash and cash 4,466,858 2,148,865 equivalents Restricted cash and cash equivalents 22,624 23,890 included in restricted deposits Total cash, cash equivalents and $ 4,489,482 $ 2,172,755 restricted cash and cash equivalents Supplemental Disclosures: Interest payments $ 10,612 $ 11,515 Income tax payments $ 1,438 $ 17,497
We regularly review the following key operating and Non-GAAP financial metrics, to evaluate our business, measure our performance, identify trends in our business, prepare financial projections, and make strategic decisions. We believe these operational and financial measures are useful in evaluating our performance, in addition to our financial results prepared in accordance with GAAP.
Total revenue includes premium revenue (net of risk adjustment transfers), investment income, and other revenues. We believe total revenue is an important metric to assess the growth of our business, as well as the earnings potential of our investment portfolio.
MLR is a metric used to calculate medical expenses as a percentage of net premiums before ceded quota share reinsurance. The impact of the federal risk adjustment program is included in the denominator of our MLR. We believe MLR is an important metric to demonstrate the ratio of our costs to pay for healthcare of our members to the net premium before ceded quota share reinsurance.
The SG&A expense ratio reflects the Company’s selling, general, and administrative expenses, as a percentage of total revenue (net of risk adjustment transfers). We believe the SG&A expense ratio is useful to evaluate our ability to manage our overall selling, general, and administrative cost base.
Earnings (loss) from operations is the Company's total revenue less total operating expenses. We believe earnings (loss) from operations is an important primary metric for assessing operating performance.
Net income (loss) attributable to Oscar Health, Inc. is net earnings (loss) allocated to the Company after net income (loss) attributable to noncontrolling interests. It is a key indicator of the Company’s profitability and operational efficiency, allowing management to evaluate performance and make informed decisions on strategic planning, cost management, and resource allocation. 8
Adjusted EBITDA is defined as Net income (loss) for the Company and its consolidated subsidiaries before interest expense, income tax expense (benefit), and depreciation and amortization, as further adjusted for stock-based compensation and other items that are considered unusual or not representative of underlying trends of our business, where applicable for the period presented. We present Adjusted EBITDA because we believe it is frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in our industry. Adjusted EBITDA is a non-GAAP measure. Management believes that investors’ understanding of our performance is enhanced by including this non-GAAP financial measure as a reasonable basis for comparing our ongoing results of operations. We caution investors that amounts presented in accordance with our definition of Adjusted EBITDA may not be comparable to similar measures disclosed by our competitors, because not all companies and analysts calculate Adjusted EBITDA in the same manner.
By providing this non-GAAP financial measure, together with a reconciliation to the most comparable U.S. GAAP measure, Net income (loss), we believe we are enhancing investors’ understanding of our business and our results of operations, as well as assisting investors in evaluating how well we are executing our strategic initiatives. Adjusted EBITDA has limitations as an analytical tool, and should not be considered in isolation, or as an alternative to, or a substitute for, net income (loss) or other financial statement data presented in our Condensed Consolidated Financial Statements as indicators of financial performance.
The Company records premium revenue net of premiums for reinsurance contracts accounted for under reinsurance accounting. The following table reconciles total reinsurance premiums ceded and reinsurance premiums assumed, which are included as components of total premium revenue in the Condensed Consolidated Statements of Operations:
The Company records medical expenses net of reinsurance recoveries for reinsurance contracts accounted for under reinsurance accounting. The following table reconciles total medical expenses to the amount presented in the Condensed Consolidated Statements of Operations:
The risk adjustment programs in the markets the Company serves are administered federally by CMS and are designed to mitigate the potential impact of adverse selection and provide stability for health insurers. Under these programs, each plan is assigned a risk score based upon demographic information and current year claims information related to its members. Plans with lower than average risk scores generally pay into the pool, while plans with higher than average risk scores generally receive distributions. The following table provides a rollforward of the Company’s beginning and ending risk adjustment receivable and payable balances for the nine months ended September 30, 2026 and 2025:
Full text with the tables
Oscar Health, Inc.
ir.oscarhealth.com
News Release
Oscar Health Announces Financial Results for Third Quarter 2026 and Raises Full
Year 2026 Outlook
New York, NY, November 5, 2026 –
Oscar Health, Inc. (“Oscar Health” or the “Company”) (NYSE: OSCR) announced
today its financial results for the third quarter ended September 30, 2026, and
updates to its full year 2026 outlook.
“Oscar Health is on track to deliver the strongest year of financial performance
in our history, and we are raising our earnings from operations outlook for a
third time,” said Mark Bertolini, CEO of Oscar Health. “The ACA is the
foundation of a rapidly-developing individual market in America, and Oscar
Health is built to lead it. Our disciplined pricing, consumer-led products, and
technology-powered approach are driving stronger economics and position us to
grow market share and expand margin in 2027.”
Third Quarter 2026 Financial Highlights
Three Months Nine Months
Ended Ended
September 30, September 30,
(in
thousands, 2026 2025 2026 2025
except
percentages)
Total revenue $5,139,298 $2,985,984 $14,666,712 $8,896,192
Medical loss 84.0% 88.5% 78.1% 84.8%
ratio (“MLR”)
Selling,
general, and
administrati… 14.0% 17.5% 14.4% 17.3%
(“SG&A”)
expense ratio
Earnings
(loss) from $178,018 $(129,250) $1,270,738 $(62,610)
operations
Net income
(loss)
attributable $167,281 $(137,450) $1,208,085 $(90,540)
to Oscar
Health, Inc.
Adjusted $206,852 $(101,453) $1,349,273 $27,971
EBITDA(1)
(1) Adjusted
EBITDA is a
non-GAAP
measure. See
“Key
Operating and
Non-GAAP
Financial
Metrics -
Adjusted
EBITDA” in
this release
for a
reconciliati…
to net
income, the
most directly
comparable
GAAP measure,
and for
information
regarding
Oscar
Health’s use
of Adjusted
EBITDA.
As of September 30,
Effectuated Membership by Offering 2026 2025
Individual and Small Group(1) 2,691,885 2,111,736
Cigna+Oscar(2) — 5,168
Total Members(3) 2,691,885 2,116,904
(1) Membership includes members enrolled
through a Custom Health Option and
Individual Care Expense Arrangement
(“CHOICE”). 2025 membership includes
small group members. The Company no
longer offers small group plans
effective December 15, 2024.
(2) Represents total membership for our
former co-branded partnership with
Cigna. We did not renew the Cigna+Oscar
Small Group arrangement after its
initial term ended on December 31, 2024.
(3) Represents effectuated members.
Effectuated members are those who are
actively enrolled in one of our plans
and whose required premium payments have
either been made or are within the
payment grace period. A member covered
under more than one of our health plans
counts as a single member for the
purposes of this metric.
2026
Financial
Guidance
Summary
Prior Full Updated Full
Year 2026 Year 2026
Outlook Outlook
(in
thousands, Low High Low High
except
percentage…
Total $18.7 $19.0 $19.0 billion $19.3
revenue(1) billion billion billion
Medical
loss 81.0% 82.0% 80.5% 81.5%
ratio(2)
SG&A
expense 15.6% 16.1% 15.1% 15.6%
ratio(3)
Earnings
from $600 million $800 million $850 million $950 million
operations…
(1) Total
revenue
includes
premium
revenue
(net of
risk
adjustment
transfers),
investment
income, and
other
revenue. We
believe
total
revenue is
an
important
metric to
assess the
growth of
our
business,
as well as
the
earnings
potential
of our
investment
portfolio.
(2) Medical
loss ratio
(MLR) is a
metric
used to
calculate
medical
expenses as
a
percentage
of net
premiums
before
ceded
quota share
reinsuranc…
We believe
MLR
is an
important
metric to
demonstrate
the ratio
of our
costs to
pay for the
healthcare
of our
members to
the net
premiums
before
ceded quota
share
reinsuranc…
(3)
Selling,
general,
and
administra…
(SG&A)
expense
ratio is
calculated
as
selling,
general and
administra…
expenses as
a
percentage
of total
revenue
(net of
risk
adjustment
transfers).
We believe
the SG&A
expense
ratio is
useful to
evaluate
our ability
to manage
our overall
selling,
general,
and
administra…
cost base.
(4)
Earnings
from
operations
is the
Company's
total
revenue
less total
operating
expenses.
We believe
earnings
from
operations
is an
important
primary
metric for
assessing
operating
performanc…
1
Oscar Health, Inc.
News Release
Third Quarter 2026 Key Metrics and Non-GAAP Financial Metrics
• Total revenue was approximately $5.1 billion for the third quarter of 2026
compared to $3.0 billion for the third quarter of 2025. The increase was driven
by rate increases and higher membership. Revenue for the third quarter of 2026
included a $250 million benefit from updated risk adjustment estimates, driven
by favorable development in the Company’s risk scores relative to the market and
modestly favorable market morbidity relative to expectations.
• The medical loss ratio was 84.0% for the third quarter of 2026 compared to
88.5% for the third quarter of 2025. The decrease was primarily driven by our
disciplined pricing strategy. The Company had $42 million of favorable prior
period development in the third quarter of 2026 compared to $84 million of
favorable prior period development in the third quarter of 2025.
• The SG&A expense ratio was 14.0% for the third quarter of 2026 compared to
17.5% for the third quarter of 2025. The decrease was primarily due to lower
risk adjustment as a percentage of premium, greater fixed cost leverage, and
disciplined expense management.
• Earnings from operations were $178.0 million for the third quarter of 2026
compared to a loss from operations of $129.3 million for the third quarter of
2025. The significant increase reflects strong operating performance driven
primarily by improved underwriting performance.
• Net income attributable to Oscar Health, Inc. was $167.3 million, or $0.49 of
diluted earnings per share, for the third quarter of 2026 compared to net loss
attributable to Oscar Health, Inc. of $137.5 million, or $(0.53) of diluted loss
per share, for the third quarter of 2025.
• Adjusted EBITDA was $206.9 million for the third quarter of 2026 compared to
an adjusted EBITDA loss of $101.5 million for the third quarter of 2025.
2
Oscar Health, Inc.
News Release
Quarterly Conference Call Details
Oscar Health will host a conference call to discuss its financial results today,
November 5, 2026, at 8:00 a.m. (ET). A live audio webcast will be available
online via the Investor Relations page of Oscar Health’s website at
ir.oscarhealth.com. A replay of the webcast will be available for on-demand
listening shortly after the completion of the call, at the same web link, and
will remain available for approximately 90 days.
Non-GAAP Financial Information
This release presents adjusted EBITDA, a non-GAAP financial metric, which is
provided as a complement to the results provided in accordance with accounting
principles generally accepted in the United States of America (“GAAP”). A
reconciliation of historical non-GAAP financial information to the most directly
comparable GAAP financial measure is provided in the accompanying tables found
at the end of this release. For more information regarding adjusted EBITDA,
please see “Key Operating and Non-GAAP Financial Metrics” below.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements other than
statements of historical fact contained herein are forward-looking statements.
These statements include, but are not limited to, statements about our financial
outlook and estimates, including Total revenue, Medical loss ratio, SG&A expense
ratio, Earnings (loss) from operations, and other financial performance metrics,
and the related underlying assumptions, our business and financial prospects,
including management’s plans and objectives for future operations, expectations
and business strategy, such as our margins, market share and profitability, and
industry and market dynamics and expected trends. In some cases, you can
identify forward-looking statements by terms such as “may,” “will,” “should,”
“expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,”
“contemplates,” “believes,” “estimates,” “forecasts,” “predicts,” “potential,”
or “continues” or the negative of these terms or other similar expressions.
Accordingly, we caution you that any such forward-looking statements are not
guarantees of future performance and are subject to risks, assumptions, and
uncertainties that are difficult to predict and generally beyond our control.
Although we believe that the expectations reflected in these forward-looking
statements are reasonable as of the date made, there are or will be important
factors that could cause our actual results to differ materially from those
indicated in these forward-looking statements, including, but not limited to,
the following: our ability to execute our strategy and manage our growth
effectively (including our ability to successfully integrate strategic
acquisitions); our ability to retain and expand our member base; our ability to
accurately estimate our incurred medical expenses or overall market morbidity,
or effectively manage our medical costs or related administrative costs;
unanticipated results of, or changes to, risk adjustment programs or our
estimates thereof; evolving federal or state laws or regulations (including any
changes in the interpretation or enforcement of existing laws and regulations),
including changes with respect to the Patient Protection and Affordable Care Act
(“ACA”) and any regulations enacted thereunder, the expiration of the enhanced
Advanced Premium Tax Credits, the implementation of new program integrity rules,
such as ID proofing rules, and rules pursuant to the Notice of Benefit and
Payment Parameters for policy year 2027, the potential funding of a cost-sharing
reduction program, or other government actions, such as the imposition of
tariffs; our ability to achieve or maintain profitability in the future; our
ability to arrange for the delivery of quality care and maintain good relations
with brokers and the physicians, hospitals, and other providers within and
outside our provider networks; our ability to comply with ongoing, complex and
evolving regulatory requirements, including capital reserve and surplus
requirements and applicable performance standards; changes or developments in
the regulation of health insurance markets in the United States; our, or any of
our vendors’, ability to comply with laws, regulations, and standards related to
the handling of information about individuals or applicable consumer protection
laws, including as a result of our participation in government-sponsored
programs; the ability of our health insurance and Health Maintenance
Organization subsidiaries to make payments of dividends or distributions to us,
including to fund our business strategy; our ability to utilize quota share
reinsurance to meet our capital and surplus requirements and protect against
downside risk on medical claims; adverse market conditions resulting in our
investment portfolio suffering losses or reducing our ability to meet our
financing needs; unfavorable or otherwise costly outcomes of lawsuits, audits,
investigations, and other third party claims that may arise from the extensive
laws and regulations to which we are subject, such as fraud, waste and abuse
laws; incurrence of data security breaches of our or our partners’ information
and technology systems; heightened competition in the markets in which we
participate; our ability to attract and retain qualified personnel;
uncertainties associated with our utilization of certain artificial intelligence
and machine learning models; our ability to detect and prevent material
weaknesses or significant control deficiencies in our internal controls over
financial reporting or other failure to maintain an effective system of internal
controls; adverse publicity or other adverse consequences related to our dual
class structure or “controlled company” status; and the other factors set forth
under the caption “Risk Factors” in our Annual Report on Form 10-K for the year
ended December 31, 2025, filed with the Securities and Exchange Commission
(“SEC”), and our other filings with the SEC.
3
Oscar Health, Inc.
News Release
You are cautioned not to place undue reliance on any forward-looking statements
made in this press release. Any forward-looking statement speaks only as of the
date as of which it is made, and, except as otherwise required by law, we do not
undertake any obligation to publicly update or review any forward-looking
statement, whether as a result of new information, future developments or
otherwise. New factors emerge from time to time, and it is not possible for us
to predict which will arise.
About Oscar Health
Oscar Health, Inc. (NYSE: OSCR) is a leading consumer healthcare company that
gives people power over their healthcare. Oscar Health serves millions of
consumers, employers, brokers, and partners through Oscar Insurance, Lucie
Health Marketplace, and Trove Group. Together these businesses deliver
exceptional lifestyle products and technology platforms that make healthcare
easy to choose, use, and experience. Learn more at OscarHealth.com.
Investor Contact
:
Chris Potochar
VP of Investor Relations
[email protected]
Media Contact:
Dalya Browne
Senior Director, External Communications
[email protected]
Source: Oscar Health, Inc.
4
Oscar Health, Inc.
News Release
Oscar Health, Inc.
Condensed
Consolidated Statements of Operations
(unaudited)
(in
thou… Three Nine
exce… Months Months
per Ended Ended
share Septem… Septe…
amou… 30, 30,
Reve… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Prem… $ 5,041… $ 2,923,… $ 14,412… $ 8,723…
Inve… 91,016 53,215 236,424 153,3…
inco…
Other 6,295 8,801 18,108 19,628
reve…
Total 5,139… 2,985,… 14,666… 8,896…
reve…
Oper…
Expe…
Medi… 4,232… 2,586,… 11,257… 7,398…
Sell…
gene… 721,8… 521,592 2,119,… 1,538…
and
admi…
Depr…
and 6,543 7,312 19,621 21,012
amor…
Total
oper… 4,961… 3,115,… 13,395… 8,958…
expe…
Earn…
(los… 178,0… -129,2… 1,270,… -62,6…
from
oper…
Inte… 4,726 6,857 14,818 18,698
expe…
Other
expe… -2,089 3,184 -1,245 3,308
(inc…
Earn…
(los…
befo… 175,3… -139,2… 1,257,… -84,6…
inco…
taxes
Inco…
tax 8,077 -1,807 49,010 5,853
expe…
(ben…
Net
inco… 167,3… -137,4… 1,208,… -90,4…
(los…
Less:
Net
inco…
(los… 23 -34 70 71
attr…
to
nonc…
inte…
Net
inco…
(los…
attr… $ 167,2… $ -137,4… $ 1,208,… $ -90,5…
to
Oscar
Heal…
Inc.
Earn…
(los…
per
Share
Basic $ 0.54 $ -0.53 $ 3.98 $ -0.35
Dilu… $ 0.49 $ -0.53 $ 3.59 $ -0.35
Weig…
Aver…
Comm…
Shar…
Outs…
Basic 309,3… 259,273 303,259 255,4…
Dilu… 346,4… 259,273 339,281 255,4…
5
Oscar Health, Inc.
News Release
Oscar Health, Inc.
Condensed
Consolidated Balance Sheets
(unaudited)
(in thousands,
except per September 30, December 31,
share amounts) 2026 2025
──────────────────────────────────────────────────────────────────────────────
Assets
Current Assets:
Cash and cash $ 4,466,858 $ 2,774,151
equivalents
Short-term 3,021,732 1,216,461
investments
Accounts
receivable (net
of allowance
for credit 303,302 362,682
losses of
$19,131 and
$7,226)
Reinsurance 270,643 99,750
recoverable
Receivables 193,793 136,029
from CMS
Other current 59,831 24,331
assets
Total current 8,316,159 4,613,404
assets
Long-term 1,441,909 1,470,987
investments
Property,
equipment, and 109,312 88,350
capitalized
software, net
Restricted 27,484 32,951
deposits
Other assets 114,116 119,719
Total assets $ 10,008,980 $ 6,325,411
Liabilities and
Stockholders'
Equity
Current
Liabilities:
Payables to CMS $ 4,626,054 $ 2,730,095
Benefits 1,924,075 1,455,385
payable
Accounts
payable and 589,220 507,325
other
liabilities
Unearned 160,392 166,203
premiums
Reinsurance 1,711 3,579
payable
Total current 7,301,452 4,862,587
liabilities
Long-term debt 432,410 430,095
Other 49,324 51,994
liabilities
Total 7,783,186 5,344,676
liabilities
Commitments and
contingencies
Stockholders'
Equity
Class A common
stock ($0.00001
par
value; 825,000
thousand shares
authorized,
275,454
thousand and
261,851 3 3
thousand shares
outstanding as
of
September 30,
2026 and
December 31,
2025,
respectively)
Class B common
stock ($0.00001
par
value; 82,500
thousand shares
authorized,
35,176 thousand
and 35,838 — —
thousand shares
outstanding as
of
September 30,
2026 and
December 31,
2025,
respectively)
Treasury stock
(315 thousand
shares as
of September -2,923 -2,923
30, 2026 and
December 31,
2025)
Additional 4,353,570 4,256,972
paid-in capital
Accumulated -2,086,349 -3,294,434
deficit
Accumulated
other
comprehensive -41,664 18,030
income
(loss)
Total Oscar
Health, Inc. 2,222,637 977,648
stockholders'
equity
Noncontrolling 3,157 3,087
interests
Total
stockholders' 2,225,794 980,735
equity
Total
liabilities and $ 10,008,980 $ 6,325,411
stockholders'
equity
6
Oscar Health, Inc.
News Release
Oscar Health, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands)
Cash Flows from Nine Months Ended
Operating September 30,
Activities: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income (loss) $ 1,208,155 $ -90,469
Adjustments to
reconcile net income
(loss) to net cash
provided by
operating
activities:
Change in provision 11,905 -24,020
for credit losses
Stock-based 58,914 69,569
compensation expense
Depreciation and 19,592 21,012
amortization expense
Amortization of debt 3,339 774
issuance costs
Net accretion of -22,975 -23,066
investments
Deferred taxes -4,313 -175
Net realized gain on
sale of financial -1,907 -1,302
instruments
Changes in assets
and liabilities:
(Increase) /
decrease in:
Reinsurance -170,893 132,146
recoverable
Accounts receivable 47,474 -54,402
Receivables from CMS -57,764 -78,240
Other assets -21,608 -29,759
Increase /
(decrease) in:
Payables to CMS 1,895,959 266,501
Benefits payable 468,691 207,665
Accounts payable and 83,847 58,061
other liabilities
Unearned premiums -5,811 2,727
Reinsurance payable -1,868 -34,071
Net cash provided by
operating 3,510,737 422,951
activities
Cash Flows from
Investing
Activities:
Sale of investments 1,149,495 134,231
Maturity and
paydowns of 1,614,749 478,173
investments
Change in restricted 211 3,225
deposits
Purchase of -4,578,517 -780,673
investments
Purchase of
property, equipment, -31,864 -27,310
and
capitalized software
Net cash used in -1,845,926 -192,354
investing activities
Cash Flows from
Financing
Activities:
Proceeds from — 410,000
long-term debt
Proceeds from
exercise of stock
options 41,828 42,192
and stock purchase
agreement
Tax payments related
to net settlement -11,920 -4,035
of share-based
awards
Purchase of capped
calls related to — -34,440
convertible notes
Payments of debt -5,990 -22,677
issuance costs
Earn-out liability -3,370 —
payout
Net cash provided by
financing 20,548 391,040
activities
Increase in cash,
cash equivalents and 1,685,359 621,637
restricted cash
equivalents
Cash, cash
equivalents,
restricted cash 2,804,123 1,551,118
and cash
equivalents—beginni…
of period
Cash, cash
equivalents,restric…
cash 4,489,482 2,172,755
and cash
equivalents—end of
period
Cash and cash 4,466,858 2,148,865
equivalents
Restricted cash and
cash equivalents 22,624 23,890
included in
restricted deposits
Total cash, cash
equivalents and $ 4,489,482 $ 2,172,755
restricted cash and
cash equivalents
Supplemental
Disclosures:
Interest payments $ 10,612 $ 11,515
Income tax payments $ 1,438 $ 17,497
7
Oscar Health, Inc.
News Release
Key Operating and Non-GAAP Financial Metrics
We regularly review the following key operating and Non-GAAP financial metrics,
to evaluate our business, measure our performance, identify trends in our
business, prepare financial projections, and make strategic decisions. We
believe these operational and financial measures are useful in evaluating our
performance, in addition to our financial results prepared in accordance with
GAAP.
Total Revenue
Total revenue includes premium revenue (net of risk adjustment transfers),
investment income, and other revenues. We believe total revenue is an important
metric to assess the growth of our business, as well as the earnings potential
of our investment portfolio.
MLR
MLR is a metric used to calculate medical expenses as a percentage of net
premiums before ceded quota share reinsurance. The impact of the federal risk
adjustment program is included in the denominator of our MLR. We believe MLR is
an important metric to demonstrate the ratio of our costs to pay for healthcare
of our members to the net premium before ceded quota share reinsurance.
Three Nine
(in Mont… Mont…
tho… Ended Ended
exc… Sept… Sept…
per… 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
cla…
bef…
ced… $ 4,23… $ 2,58… $ 11,2… $ 7,39…
quo…
sha…
rei…
Net
pre…
bef…
ced… $ 5,04… $ 2,92… $ 14,4… $ 8,72…
quo…
sha…
rei…
Med…
Loss
Rat… 84.0 % 88.5 % 78.1 % 84.8 %
div…
by
B)
SG&A Expense Ratio
The SG&A expense ratio reflects the Company’s selling, general, and
administrative expenses, as a percentage of total revenue (net of risk
adjustment transfers). We believe the SG&A expense ratio is useful to evaluate
our ability to manage our overall selling, general, and administrative cost
base.
Earnings (Loss) from Operations
Earnings (loss) from operations is the Company's total revenue less total
operating expenses. We believe earnings (loss) from operations is an important
primary metric for assessing operating performance.
Net Income (Loss) Attributable to Oscar Health, Inc.
Net income (loss) attributable to Oscar Health, Inc. is net earnings (loss)
allocated to the Company after net income (loss) attributable to noncontrolling
interests. It is a key indicator of the Company’s profitability and operational
efficiency, allowing management to evaluate performance and make informed
decisions on strategic planning, cost management, and resource allocation.
8
Oscar Health, Inc.
News Release
Adjusted EBITDA
Adjusted EBITDA is defined as Net income (loss) for the Company and its
consolidated subsidiaries before interest expense, income tax expense (benefit),
and depreciation and amortization, as further adjusted for stock-based
compensation and other items that are considered unusual or not representative
of underlying trends of our business, where applicable for the period presented.
We present Adjusted EBITDA because we believe it is frequently used by
securities analysts, investors, and other interested parties in the evaluation
of companies in our industry. Adjusted EBITDA is a non-GAAP measure. Management
believes that investors’ understanding of our performance is enhanced by
including this non-GAAP financial measure as a reasonable basis for comparing
our ongoing results of operations. We caution investors that amounts presented
in accordance with our definition of Adjusted EBITDA may not be comparable to
similar measures disclosed by our competitors, because not all companies and
analysts calculate Adjusted EBITDA in the same manner.
By providing this non-GAAP financial measure, together with a reconciliation to
the most comparable U.S. GAAP measure, Net income (loss), we believe we are
enhancing investors’ understanding of our business and our results of
operations, as well as assisting investors in evaluating how well we are
executing our strategic initiatives. Adjusted EBITDA has limitations as an
analytical tool, and should not be considered in isolation, or as an alternative
to, or a substitute for, net income (loss) or other financial statement data
presented in our Condensed Consolidated Financial Statements as indicators of
financial performance.
Three Nine
Months Months
Ended Ended
(in Septem… Septem…
thousa… 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
income $ 167,304 $ -137,484 $ 1,208,… $ -90,469
(loss)
Intere… 4,726 6,857 14,818 18,698
expense
Other
expens… -2,089 3,184 -1,245 3,308
(incom…
Income
tax 8,077 -1,807 49,010 5,853
expense
(benef…
Earnin…
(loss) 178,018 -129,250 1,270,… -62,610
from
operat…
Deprec…
and 6,543 7,312 19,621 21,012
amorti…
Stock-… 22,291 20,485 58,914 69,569
compen…
Adjust… $ 206,852 $ -101,453 $ 1,349,… $ 27,971
EBITDA
(1)
Repres…
non-ca…
expens…
related
to
equity…
compen…
progra…
which
vary
from
period
to
period
depend…
on
various
factors
includ…
the
timing,
number,
and the
valuat…
of
awards.
Additi…
these
expens…
are
report…
net of
any
stock-…
compen…
that
has
been
capita…
for
softwa…
develo…
costs.
9
Oscar Health, Inc.
News Release
Appendix
10
Oscar Health, Inc.
News Release
Supplemental Financial Information
Premium
The Company records premium revenue net of premiums for reinsurance contracts
accounted for under reinsurance accounting. The following table reconciles total
reinsurance premiums ceded and reinsurance premiums assumed, which are included
as components of total premium revenue in the Condensed Consolidated Statements
of Operations:
Three Nine
Months Months
Ended Ended
(in Septem… Septem…
thous… 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Direct
policy $ 5,724,… $ 3,646,3… $ 17,421… $ 10,478,…
premi…
Risk
adjus… -677,2… -727,538 -2,991… -1,793,…
trans…
Reins…
premi… -5,133 -3,048 -15,740 -8,280
ceded
Assum… 37 8,246 -1,626 46,302
premi…
Premi… $ 5,041,… $ 2,923,9… $ 14,412… $ 8,723,2…
(1)
The
Compa…
did
not
renew
the
Cigna…
Small
Group
arran…
with
Cigna
Health
and
Life
Insur…
Compa…
after
its
initi…
term
ended
on
Decem…
31,
2024.
Follo…
termi…
the
Compa…
has
been
provi…
trans…
and
run-o…
servi…
and
will
conti…
to
provi…
such
servi…
throu…
Decem…
31,
2026.
The
Compa…
also
conti…
to
share
in
premi…
and
claims
for
plans
sold
or
issued
prior
to
Decem…
15,
2024.
Medical Expenses
The Company records medical expenses net of reinsurance recoveries for
reinsurance contracts accounted for under reinsurance accounting. The following
table reconciles total medical expenses to the amount presented in the Condensed
Consolidated Statements of Operations:
Three Nine
Months Months
Ended Ended
(in Septem… Septem…
thous… 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Direct
claims $ 4,308,… $ 2,626,8… $ 11,474… $ 7,457,2…
incur…
Ceded
reins… -76,116 -47,750 -217,1… -100,965
claims
Assum…
reins… 897 7,250 -425 42,688
claims
Medic… $ 4,232,… $ 2,586,3… $ 11,257… $ 7,398,9…
expen…
11
Oscar Health, Inc.
News Release
Risk Adjustment
The risk adjustment programs in the markets the Company serves are administered
federally by CMS and are designed to mitigate the potential impact of adverse
selection and provide stability for health insurers. Under these programs, each
plan is assigned a risk score based upon demographic information and current
year claims information related to its members. Plans with lower than average
risk scores generally pay into the pool, while plans with higher than average
risk scores generally receive distributions. The following table provides a
rollforward of the Company’s beginning and ending risk adjustment receivable and
payable balances for the nine months ended September 30, 2026 and 2025:
Ni… Ni…
Mo… Mo…
En… En…
Se… Se…
30, 30,
20… 20…
──────────────────────────────────────────────────────────────────────────────
Ri… Ri… Net Ri… Ri… Net
(… Ad… Ad… Ri… Ad… Ad… Ri…
t… Re… Pa… Ad… Re… Pa… Ad…
Pa… Pa…
B… $ 56… $ 2,… $ 2,… $ 64… $ 1,5… $ 1,4…
b…
C…
in
a…
C… $ 45… $ 3,… $ 3,… $ 41… $ 1,7… $ 1,7…
y…
P… 56… -2… -5… 16… 92,… 76,…
y…
C…
in $ 10… $ 3,… $ 2,… $ 58… $ 1,8… $ 1,7…
a…
n…
P…
P… $ 27… $ 2,… $ 2,… $ 30… $ 1,6… $ 1,6…
y…
P… $ 27… $ 2,… $ 2,… $ 30… $ 1,6… $ 1,6…
E…
b…
C… $ 45… $ 3,… $ 3,… $ 41… $ 1,7… $ 1,7…
y…
P… 85… 29… -5… 50… 11,… -38…
y…
E… $ 13… $ 3,… $ 2,… $ 92… $ 1,7… $ 1,6…
b…
(…
T…
t…
i…
r…
a…
d…
v…
(…
r…
a…
p…
T…
b…
at
t…
b…
of
e…
y…
p…
p…
to
p…
p…
y…
12